CKD-5D患者两年皮质骨与松质骨丢失:生化与临床预测因素
这项为期两年的前瞻性研究对89例慢性透析(CKD-5D)患者用DXA和QCT测量基线与每年骨密度,并记录临床与血清指标。QCT显示全髋总骨密度两年下降5.9%,皮质质量与体积分别下降7.3%和10.0%,松质体积增加5.9%,脊柱骨密度无变化。基线骨密度较高和透析龄较短者骨丢失更多,作用于中枢神经系统的降压药具保护作用,BSAP和硬骨素可预测骨丢失。
要点
- QCT显示全髋总骨密度两年下降5.9%,DXA显示下降3.1%,脊柱骨密度无变化。
- 全髋皮质质量下降7.3%、皮质体积下降10.0%,松质体积增加5.9%。
- 基线骨密度较高和透析龄较短者骨丢失更多,中枢作用降压药对骨密度和皮质参数有保护作用。
核心结论
- 髋部存在严重皮质骨丢失,QCT识别最佳。
- 透析龄较短和既存骨丢失较少者骨丢失更多,中枢作用降压药治疗具保护作用。
- BSAP和硬骨素是骨丢失的有用标志物。
研究设计与样本
- 前瞻性两年研究,纳入89例慢性肾脏病透析(CKD-5D)患者。
- 基线与第1、2年用双能X线吸收法(DXA)和定量计算机断层扫描(QCT)测量骨密度,同时采血并记录临床变量。
- 未给予研究性治疗。
主要发现
- 全髋骨密度两年变化:QCT为-5.9%,DXA为-3.1%(p<0.001)。
- 脊柱骨密度无变化。
- QCT全髋皮质质量下降7.3%、皮质体积下降10.0%,松质体积增加5.9%(ps<0.001)。
- 骨密度变化不随年龄、BMI、种族、糖尿病、吸烟或运动而变化。
- 基线骨密度较高和透析龄较短者骨丢失更多(p<0.05)。
关键数值与推荐
- 维生素D类似物和磷结合剂对骨丢失无保护作用;西那卡塞单变量有保护作用,多变量分析无保护作用。
- 中枢作用降压药对骨密度、皮质质量、皮质体积丢失有保护作用(ps<0.05),对松质质量亦有保护作用(p=0.007),校正后仍存在。
- BSAP与骨密度、皮质质量和体积变化相关(p<0.01),硬骨素呈反向相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This prospective two-year study of patients on chronic dialysis measured changes in bone mineral density (BMD). Patients with higher baseline BMD and shorter dialysis vintage lost more bone. Treatment with anti-hypertensives acting on the central nervous system was protective against bone loss. Baseline serum levels of sclerostin and bone-specific alkaline phosphatase predicted bone loss. INTRODUCTION: This prospective 2-year study of chronic kidney disease on dialysis (CKD-5D) patients assessed trabecular and cortical bone loss at the hip and spine and examined potential demographic, clinical, and serum biochemical predictors of bone loss. METHODS: Eighty-nine CKD-5D patients had baseline, year 1, and year 2 bone mineral density (BMD) measurements using dual X-ray absorptiometry (DXA) and quantitative computed tomography (QCT); concurrent blood samples were drawn and clinical variables recorded. No study treatments occurred. RESULTS: The 2-year total hip BMD change was - 5.9% by QCT and - 3.1% by DXA (p < 0.001). Spinal BMD was unchanged. QCT total hip cortical mass and volume decreased (- 7.3 and - 10.0%); trabecular volume increased by 5.9% (ps < 0.001). BMD changes did not vary with age, BMI, race, diabetes, smoking, or exercise. Patients with higher baseline BMD and shorter dialysis vintage lost more bone (p < 0.05). Vitamin D analogs and phosphate binders were not protective against bone loss; cinacalcet was protective by univariate but not by multivariable analysis. CNS-affecting antihypertensives were protective against loss of BMD, cortical mass, cortical volume (ps < 0.05) and trabecular mass (p = 0.007). These effects remained after adjustment. BSAP correlated with changes in BMD, cortical mass, and volume (p < 0.01) as did sclerostin (inversely). CONCLUSIONS: There was severe cortical bone loss at the hip best recognized by QCT. Patients with shorter dialysis vintage and less pre-existing bone loss lost more bone, while treatment with CNS-acting antihypertensives was protective. BSAP and sclerostin were useful markers of bone loss.
引用
- Malluche HH, Monier-Faugere MC, Blomquist G, et al. Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors. Osteoporos Int. 2017. PMID: 28993865. doi:10.1007/s00198-017-4228-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。